melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery inflammation/arthritis

Experimental Autoimmune Encephalomyelitis (EAE) Model of Multiple Sclerosis

Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis.  This model is produced by administering a myelin basic protein peptide (MBP) fragment that induces an autoimmune response directed to the myelin sheath surrounding motor neurons.  Demyelination of neurons within the CNS leads to impaired locomotor function and mirrors symptoms of the human disease.  The disease, and the model, appear in exacerbations and remissions and are characterized by loss of nerve conduction and chronic progression of disability.  This study asses the progression of locomotor dysfunction in mice subjected to EAE. 

                    EAE model of Mulitple sclerosis

Figure A: Body weights.  The untreated mice showed an increase in body weight throughout the study.  The FTY-720 and vehicle treated mice displayed a decrease in body weights following injection of PLP/CFA, which was maintained throughout the study. 

 

Figure B: Average clinical scores over time.  Clinical scores were assessed daily beginning on Day 7 and ending on Day 21.  Based on the clinical score system, vehicle treated mice showed an increase in impairment severity throughout the course of the study.  The FTY-720 treated mice showed a decrease in impairment following drug administration that became statistically significant when compared to vehicle treated mice on days 17-21.  Data are mean ± SEM; * p<0.05, **p<0.01 compared to vehicle. 

 

Clnical Scoring:

Mice were randomized according to clnical score on Day 7 of the study.  Clnical scoring was completed so that each mouse received one score per day.  Clnical scores were evaluated using the following scale:

Clinical Score Symptoms
0 No clinical signs; normal activity
1 Limp tail or hind limb weakness, but not both
2 Limp tail and hind limb weakness
3 Partial hind limb paralysis
4 Complete hind limb paralysis
5 Moribund state; death by EAE

 

 

If you are interested in learning more about the EAE Model of Multiple Sclerosis, please contact models@meliordiscovery.com to start the conversation.